Effect of fenfluramine on growth hormone and prolactin secretion in obese subjects. 1987

L Altomonte, and A Zoli, and F Alessi, and G Ghirlanda, and R Manna, and A V Greco
Istituto di Clinica Medica, Università Cattolica S. Cuore, Roma, Italia.

Obese subjects show a subnormal growth hormone (GH) and prolactin (PRL) release in response to a variety of stimuli. Fenfluramine, an anorexiant drug used in obesity therapy, may have some effects on hypothalamic-pituitary function mediated by serotoninergic stimulation. The present investigation in obese subjects was carried out to study the effects of fenfluramine (60 mg orally) on GH and PRL secretion after intravenous arginine infusion. Ten volunteer obese females were studied and compared with 10 volunteer normal weight controls. In the obese group the GH response to arginine was significantly lower than in control group. Fenfluramine administration restored the subnormal GH response to arginine in obese subjects. The PRL response to arginine in obese women was subnormal. Fenfluramine administration restored the response of PRL to arginine infusion to normal. In conclusion, fenfluramine--under acute circumstances--enhances the hypothalamic-pituitary response to arginine in obese subjects. The decreased GH and PRL output in obese subjects is not due to an absolute hormonal deficiency and this effect of fenfluramine on GH secretion may--due to its lipolysis stimulation--be useful in obesity treatment.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009765 Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
D011388 Prolactin A lactogenic hormone secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). It is a polypeptide of approximately 23 kD. Besides its major action on lactation, in some species prolactin exerts effects on reproduction, maternal behavior, fat metabolism, immunomodulation and osmoregulation. Prolactin receptors are present in the mammary gland, hypothalamus, liver, ovary, testis, and prostate. Lactogenic Hormone, Pituitary,Mammotropic Hormone, Pituitary,Mammotropin,PRL (Prolactin),Hormone, Pituitary Lactogenic,Hormone, Pituitary Mammotropic,Pituitary Lactogenic Hormone,Pituitary Mammotropic Hormone
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D005260 Female Females
D005277 Fenfluramine A centrally active drug that apparently both blocks serotonin uptake and provokes transport-mediated serotonin release. Fintepla,Fenfluramine Hydrochloride,Fenfluramine Hydrochloride, (+-)-Isomer,Fenfluramine Hydrochloride, R-Isomer,Fenfluramine, (+-)-Isomer,Fenfluramine, R-Isomer,Isomeride,Pondimin,Fenfluramine Hydrochloride, R Isomer,Fenfluramine, R Isomer,Hydrochloride, Fenfluramine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001120 Arginine An essential amino acid that is physiologically active in the L-form. Arginine Hydrochloride,Arginine, L-Isomer,DL-Arginine Acetate, Monohydrate,L-Arginine,Arginine, L Isomer,DL Arginine Acetate, Monohydrate,Hydrochloride, Arginine,L Arginine,L-Isomer Arginine,Monohydrate DL-Arginine Acetate

Related Publications

L Altomonte, and A Zoli, and F Alessi, and G Ghirlanda, and R Manna, and A V Greco
January 1981, Hormone research,
L Altomonte, and A Zoli, and F Alessi, and G Ghirlanda, and R Manna, and A V Greco
January 1966, Guy's Hospital reports,
L Altomonte, and A Zoli, and F Alessi, and G Ghirlanda, and R Manna, and A V Greco
May 2001, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity,
L Altomonte, and A Zoli, and F Alessi, and G Ghirlanda, and R Manna, and A V Greco
December 1983, Clinical endocrinology,
L Altomonte, and A Zoli, and F Alessi, and G Ghirlanda, and R Manna, and A V Greco
December 1974, Polskie Archiwum Medycyny Wewnetrznej,
L Altomonte, and A Zoli, and F Alessi, and G Ghirlanda, and R Manna, and A V Greco
March 1986, Endocrinology,
L Altomonte, and A Zoli, and F Alessi, and G Ghirlanda, and R Manna, and A V Greco
January 1990, European journal of clinical pharmacology,
L Altomonte, and A Zoli, and F Alessi, and G Ghirlanda, and R Manna, and A V Greco
August 1978, Archivos de farmacologia y toxicologia,
L Altomonte, and A Zoli, and F Alessi, and G Ghirlanda, and R Manna, and A V Greco
January 1976, Annales d'endocrinologie,
L Altomonte, and A Zoli, and F Alessi, and G Ghirlanda, and R Manna, and A V Greco
September 1977, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
Copied contents to your clipboard!